CSE:BE;
OTCQX:BLEVF
PRESS RELEASE
Beleave Receives License to Produce Cannabis Oils from Health Canada
TORONTO, ONTARIO - (Dec. 4, 2017) - Beleave Inc. ("Beleave" or the "Company") (CSE:BE)(OTCQX:BLEVF) is pleased to announce it has been granted a license by Health Canada to begin commercial production of cannabis oils.
“We are very pleased to be able to begin oil extraction on a commercial level,” said Beleave CEO Andrew Wnek, “The company has put a lot of time and effort into researching various extraction techniques and is looking forward to putting this knowledge to good use.”
About Beleave Inc. (CSE: BE)
Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located near Hamilton, Ontario.
For further information please contact:
Sebastian de Kloet
Phone: (905) 979 - 5173
Email: [email protected] beleave.com.
Forward-Looking Information
This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the D.O.P.E. Note being paid back in full or at all, the ability to enforce against the D.O.P.E. Note in the event of default, the ability to generate revenue through the streaming agreements, the ability to consummate transactions which are currently in discussions, requirements to obtain additional financing, timeliness of government approvals for granting of permits and licences, including licences to cultivate cannabis, completion of the facilities, where applicable, actual operating performance of the facilities, regulatory or political change, competition and other risks affecting the CW or Beleave in particular and the medical cannabis industry generally. Although it is expected that initial funding will occur by mid-October 2017, no assurances are given in this regard. There is also no assurance that any further advances under the D.O.P.E. Note will be made, nor that the parties will proceed to funding under the interim streaming agreement. Forward-looking information is based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Neither CW nor Beleave is under any obligation, and each expressly disclaims any intention or obligation, to update or revise any forward -looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.